Effect of simvastatin on endothelial dysfunction, fibrinolysis, coagulation and inflammation after aneurysmal subarachnoid hemorrhage

Completed

• Conditions: Aneurysmal subarachnoid hemorrhage; Nervous System Diseases; Aneurysmal subarachnoid haemorrhage

• Registration Number: ISRCTN45662651
• Lead Sponsor: Academic Medical Centre (AMC) (The Netherlands)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-06-29
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Patients with clinical symptoms and signs of SAH with an aneurysmal bleeding pattern on the initial computerised tomography (CT) scan. CT scan has to be performed within 48 hours after SAH onset
2. Patients with a perimesencephalic hemorrhage pattern on the initial CT scan while computed tomographic angiography (CTA) or conventional angiography has shown an appropriate aneurysm. CTA or angiography has to be performed within 48 hours after SAH onset
3. If CT scan is negative while there is evidence of bleeding in the cerebrospinal fluid (xanthochromia) and the CT-angiography has shown an aneurysm

Exclusion Criteria

1. Under 18 years of age
2. A time lapse of more than 48 hours after SAH onset
3. Patients using aspirin or warfarin
4. Patients already using statins
5. Contra-indication for simvastatin (active liver disease, liver transaminase more than three times the normal upper limit, myopathy)
6. Kidney insufficiency
7. If death appears imminent
8. Pregnancy or lactation

Study & Design

• Study Type: Interventional
• Study Design: Not specified